SCHEMBL4059592

SCHEMBL4059592

Fc1ccccc1-c1cnc2nc(COc3ccccc3)[nH]c2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.48
GRM5 P41594 3/20 0.48
RXFP1 Q9HBX9 2/20 0.48
LMNA P02545 2/20 0.48
HTT P42858 2/20 0.48
NPSR1 Q6W5P4 1/20 0.48
RAB9A P51151 10/20 0.48
NPC1 O15118 8/20 0.48
TP53 P04637 3/20 0.48
TSHR P16473 1/20 0.48
NOS3 P29474 1/20 0.44
NOS1 P29475 1/20 0.44
NOS2 P35228 1/20 0.44
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
SCD O00767 1/20 0.43
TRPA1 O75762 1/20 0.40
PRMT5 O14744 1/20 0.39
ALDH1A1 P00352 1/20 0.39
CYP3A4 P08684 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4058507 0.85 NOS3 (0.58) SMN1; SMN2GRM5RXFP1LMNAHTT
SCHEMBL4052646 0.83 SCD (0.45) SMN1; SMN2LMNARAB9ANPC1TSHR
SCHEMBL4054497 0.82 NOS3 (0.47) SMN1; SMN2LMNAHTTRAB9ANPC1
SCHEMBL4055504 0.81 SMN1; SMN2 (0.47) SMN1; SMN2RXFP1LMNAHTTNPSR1
SCHEMBL13607906 0.81 GRM5 (0.48) SMN1; SMN2GRM5RXFP1LMNAHTT
SCHEMBL4058739 0.80 NPC1 (0.47) SMN1; SMN2RAB9ANPC1TP53NOS3
SCHEMBL4062462 0.79 NOS3 (0.48) SMN1; SMN2RXFP1LMNAHTTNPSR1
SCHEMBL4051128 0.79 NOS3 (0.48) SMN1; SMN2RXFP1LMNAHTTNPSR1
SCHEMBL4055025 0.78 SMN1; SMN2 (0.47) SMN1; SMN2RXFP1LMNAHTTNPSR1
SCHEMBL4051951 0.78 SMN1; SMN2 (0.47) SMN1; SMN2RXFP1LMNAHTTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B SMN1; SMN2 4289/4885GRM5 4307/4885RXFP1 2581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.